Spinifex Pharma names new CMO
This article was originally published in Scrip
Spinifex Pharmaceuticals, a pain drug development company, has appointed Dr Ronald Marcus chief medical officer – effective immediately. He joins the Melbourne, Australia-based firm from Bristol-Myers Squibb, where he held a number of senior leadership positions within the drugmaker's neuroscience division. At Spinifex Dr Marcus will be responsible for developing the firm's lead candidate, chronic pain drug EMA401, and the company's pre-clinical pipeline.